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Fascinating progress in the understanding of the molecular biology of hepatitis C virus (HCV) was achieved recently. 
The replicon system revolutionized the investigation of HCV RNA replication and facilitated drug discovery. Novel 
systems for functional analyses of the HCV glycoproteins allowed the validation of HCV receptor candidates and the 
investigation of cell entry mechanisms. Most recently, recombinant infectious HCV could be produced in cell culture, 
rendering all steps of the viral life cycle, including entry and release of viral particles, amenable to systematic analysis. 
In this review, we summarize recent advances and discuss future research directions. 
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1. Introduction 
The hepatitis C virus (HCV) belongs to the Flaviviridae family and is the only member of the Hepacivirus genus. 
HCV infection is a major cause of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC) worldwide [1]. 
Therapeutic options are improving but are still limited and a protective vaccine is not available to date. In 50% to 80% 
acute HCV infection persists and 4% to 20% of patients with chronic hepatitis C will develop liver cirrhosis within 20 
years. In patients with liver cirrhosis, the risk to develop HCC is 1-5% per year. Current standard therapy is the 
combination of pegylated interferon-α (PEG-IFN-α) and ribavirin. Depending on the HCV genotype and other factors, 
this strategy results in a sustained virologic response in 50-80% of patients [2-5]. However, many patients do not qualify 
for or do not tolerate standard therapy [6]. Therefore, more effective and better tolerated therapeutic strategies are 
urgently needed. The development of such strategies depends on a detailed understanding of the molecular virology of 
HCV infection. 
The investigation of the HCV life cycle and pathogenesis has been complicated by the lack of efficient cell culture 
systems and small animal models. Nevertheless, significant progress could be made using heterologous expression 
systems, functional cDNA clones [7], the replicon system [8, 9], and functional HCV pseudoparticles [10, 11] (see refs. 
[12-14] for reviews). Most recently, a major milestone was the production of recombinant infectious HCV particles in cell 
culture [15-17]. The model systems, summarized in Table 1, are the current basis for the study of the HCV life cycle and 
the development of novel antiviral strategies. 
Table 1. In vitro and in vivo models to study HCV. 
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Figure 1. Life cycle of HCV. The steps of the viral life cycle are depicted schematically. The topology of HCV structural and 
nonstructural proteins at the endoplasmic reticulum (ER) membrane is shown. HCV RNA replication occurs in a specific membrane 
alteration, the membranous web (MW). IRES-mediated translation and polyprotein processing as well as membranous web 
formation and RNA replication, illustrated here as separate steps for simplicity, may occur in a tightly coupled manner. 
 
2. The replicon system 
For many years, HCV research was hampered by the extremely restricted host range and the inefficiency of in vitro 
models based on the incubation of cells in culture with HCV particles. Therefore, the establishment of a replicon system 
for HCV was a milestone in HCV research [8, 18]. The prototype subgenomic replicon utilized a particular HCV 
genotype 1b clone termed Con1. In this system, the structural region was replaced by the sequence encoding the 
neomycin phosphotransferase gene resulting in G418 resistance. Expression of the nonstructural proteins is directed by 
a heterologous encephalomyocarditis virus (EMCV) internal ribosomal entry site (IRES) downstream of the neomycin 
phosphotransferase gene. After transfection into the human HCC cell line Huh-7 G418 resistant colonies contain self-
replicating HCV RNA. Critical for the usefulness of this system was the identification of specific amino acid 
substitutions, i.e., cell culture-adaptive changes, that increased the efficiency of replication initiation by several orders of 
magnitude [9]. With the replicon system it became possible, for the first time, to study efficient and genuine HCV RNA 
replication in vitro as well as structural aspects of the replication complex, basic replication processes, virus-host cell 
interactions, and antiviral agents.  
In the last 6 years, a large panel of different replicon systems has been developed (Fig. 2). These include replicons 
from genotype 1a [19] and 2a [20], transient systems expressing easily quantifiable marker enzymes [21], replicons with 
green fluorescent protein (GFP) insertions in NS5A to track replication complexes in living cells [22], and full length 
replicons. In addition, the spectrum of permissive host cells has been expanded [23].  
The replicon system revolutionized the research on basic replication processes. However, the step of infection and 
entry as well as the release of viral progeny could not be analysed to date. Wakita and colleagues, however, generated a 
genotype 2a replicon (JFH-1) that was isolated from the serum of a patient with fulminant hepatitis C [20]. This system 
turned out to replicate very efficiently in different cell types. Furthermore, the full-length JFH-1 sequence produced 
infectious viral particles that could be passaged in cell culture [15, 17]. Further, chimeric constructs with the structural 
region of the J6 genotype 2a clone improved the infectivity of this system significantly [16]. This recombinant infectious 
HCV cell culture system represents the last major milestone in the field and renders the complete viral life cycle 
accessible to detailed analysis in vitro. 
3. Cell entry 
Surrogate models for the study of the early steps of viral life cycle have been established, including infectious 
retroviral pseudotypes displaying functional HCV glycoproteins. These pseudotypes turned out to provide a robust 
model system for the study of viral entry [10, 11]. HCV pseudoparticle infectivity is pH-dependent and restricted 
primarily to human hepatocytes and hepatocyte-derived cell lines. Thus, HCV entry likely involves transit through an 
endosomal, low pH compartment and fusion with the endosomal membrane.  
HCV E2 binds with high affinity to the large external loop of CD81, a tetraspanin found on the surface of many cell 
types including hepatocytes [24]. However, CD81 is not sufficient to mediate cell entry and several cofactors appear to 
be required. The low density lipoprotein receptor (LDLR) [25] and scavenger receptor class B type I (SR-BI) [26] have, 
among others, been proposed as components of a putative HCV receptor complex. The concept, that lipoproteins could 
play an important role for cell entry is supported by recent data from studies on HCV pseudotypes that demonstrate an 
enhancement of infectivity by certain components of human serum [27, 28]. In particular, association to high density 
lipoprotein (HDL) seems to enhance SR-BI guided cell entry and could protect viral particles from neutralizing 
antibodies [29].  
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Figure 2. Comparison of different replicon systems. A selection of different bicistronic and monocistronic replicon constructs 
including subgenomic and full-length HCV sequences is depicted schematically. Stably replicating systems are equipped among 
others with a neomycin phosphotransferase or a hygromycin phosphotransferase cassette that allow selection of cells with 
continuous RNA replication. Transient systems include a marker gene that allows quantification 48 h after transient transfection. In 
general, luciferase (Luc) is used as easily quantifiable enzyme in this context and values are normalized based on the amount of 
input RNA. Monocistronic replicon constructs avoid the translation of proteins from the heterologous encephalomyocarditis virus 
(EMCV) IRES. The resistance gene is released after cleavage via a ubiquitin sequence (Ubi). 
 
 
4. Translation and polyprotein processing 
The HCV genome consists of a 9.6-kb positive-strand 
RNA that comprises a long open reading frame flanked by 
5' and 3' noncoding regions (NCR). The 5' NCR is highly 
conserved among different HCV isolates and contains an 
IRES. The IRES directly binds the 40S ribosomal subunit 
independently of the pre-initiation factors necessary for 
cap-dependent translation. The three-dimensional 
structure of the HCV IRES bound to the 40S ribosomal 
subunit illustrates the molecular basis of this cap-
independent translation process [30]. High-resolution 
structural data on critical elements of the IRES and 
detailed characterization of the translation initiation 
complex further improves the view on the HCV 
translation initiation [31, 32]. 
Translation of the HCV genome leads to a 
polyprotein precursor that is co- and post-translationally 
processed by cellular and viral proteases to produce the 
mature structural and nonstructural proteins. The N-
terminal one-third of the polyprotein harbors the 
structural proteins core, E1 and E2 that form the viral 
particle. The structural region is followed by the p7 
polypeptide which may be involved in ion channel 
formation (see below). The nonstructural proteins 2-5B 
coordinate viral replication by the formation of a 
membrane-bound replication complex. Processing of the 
polyprotein at the core/E1, E1/E2, E2/p7, and p7/NS2 
sites by the host cell signal peptidase produces all 
structural proteins and p7. Two viral proteases are 
responsible for the maturation of the nonstructural 
proteins. The NS2-3 autoprotease cleaves at the NS2/NS3 
junction while all downstream sites are processed by the 
NS3-4A serine protease. 
5. Molecular aspects of viral proteins 
5.1  Structural proteins 
5.1.1  Core protein 
The HCV core protein is a highly basic, RNA-binding 
protein which presumably forms the viral nucleocapsid. 
Of note, the core protein has been reported to interact 
with numerous cellular proteins and to affect host cell 
functions such as gene transcription, lipid metabolism, 
apoptosis and various signaling pathways [33]. Further, it 
has been associated with the induction of steatosis and 
HCC [34-36].  
5.1.2  Envelope glycoproteins 
The envelope glycoproteins E1 and E2 are type I 
transmembrane proteins with C-terminal hydrophobic 
anchors. The ectodomains translocate to the ER lumen 
where they are modified by extensive N-linked 
glycosylation. E1 and E2 form non-covalent heterodimers 
which are believed to represent the building blocks for the 
viral envelope. The processes of particle assembly and 
release are poorly understood and have only recently 
become amenable to systematic investigation. In this 
context, structural studies on recombinant HCV particles 
confirmed earlier electron microscopy observations [15]. 
5.2  ARFP/F protein 
The synthesis of a protein encoded by an alternative 
reading frame within the core region was reported by 
several groups [37]. It was designated ARFP (alternative 
reading frame protein) or F (frameshift) protein and 
comprises up to 160 amino acids. The ARFP/F protein is 
dispensable for HCV RNA replication. Whether it is 
expressed during natural HCV infection has still to be 
clarified. 
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5.3  p7 
p7 is a 63-amino acid polypeptide located at the 
junction between the structural and nonstructural region. 
It is unknown whether p7 is packaged into viral particles. 
It is composed of two transmembrane domains and has 
recently been reported to form hexamers with ion channel 
activity [38, 39]. It is believed that p7 could be important 
for viral assembly because the corresponding protein of 
the related bovine viral diarrhea virus (BVDV) is essential 
for the production of infectious progeny virus but not for 
RNA replication [40]. 
5.4  Nonstructural proteins 
5.4.1  NS2-3 autoprotease 
The NS2/3 junction is cleaved by a remarkable 
autoprotease consisting of NS2 and the N-terminal third 
of NS3. Although NS2-3 protease activity is required for 
the replication in vivo, it is dispensable for replication of 
subgenomic replicons in vitro. It is unclear whether NS2 
fulfills any further functions after separation from NS3. 
5.4.2  NS3-4A  
NS3 is a multifunctional protein because it harbors a 
serine protease located in the N-terminal one-third that is 
responsible for the downstream cleavage in the 
nonstructural region and a NTPase/RNA helicase domain 
in the C-terminal two-thirds. NS4A, a 54-amino acid 
polypeptide, targets NS3 to intracellular membranes and 
is required as a cofactor for the NS3 serine protease. The 
crystal structure of the NS3-4A complex revealed that 
NS4A is an integral component of the enzyme core [41]. 
Surprisingly, the NS3 serine protease recently turned out 
to influence the innate cellular host defense by inhibition 
of RIG-I and TLR3 signalling [42, 43]. This observation 
renders the NS3 protease particularly attractive as an 
antiviral target [44]. Serine protease inhibitors have 
emerged as extremely efficient antiviral components in 
first 'proof-of-principle' studies in patients with chronic 
hepatitis C [45, 46].  
The enzymatic activity of the NS3 NTPase/helicase 
activity is indispensable for RNA replication. Putative 
functions during replication could be to unwind 
replicative double strand RNA intermediates, to eliminate 
RNA secondary structures or to separate the genome from 
nucleic acid binding proteins. Recent advances in the 
understanding of the molecular mechanisms of this 
enzyme could enable a specific inhibition as a novel 
antiviral strategy [47, 48]. 
5.4.3  NS4B 
Due to its very hydrophobic properties, NS4B 
belongs to the difficult-to-study HCV proteins that are 
poorly understood. So far, it is known that NS4B is a 27-
kDa integral membrane protein that localizes to an ER-
derived membranous compartment [49]. Interestingly, the 
expression of NS4B induces a specific membrane 
alteration, designated as membranous web, that serves as 
a scaffold for the formation of the viral replication 
complex [50, 51].  
5.4.4  NS5A 
NS5A is a phosphorylated zinc metalloprotein of 
unknown function. Numerous potential functions and a 
huge list of interaction partners have been described [33]. 
However, suprisingly little efforts has been devoted to a 
rigorous biochemical characterization of this protein and 
its definitive role in viral replication remains elusive. 
NS5A has initially attracted considerable interest because 
of its potential role in modulating the IFN response 
(reviewed in ref. [52]). These findings are still 
controversial, however. A striking observation was the 
concentration of cell culture adaptive replicon mutations 
within the central part of NS5A [9, 53]. Considering the 
fact that NS5A phosphorylation has an impact on 
replication efficiency, these observations support the 
concept that NS5A plays an important role in the 
regulation of viral replication [54-56]. The membrane 
association of NS5A is mediated by a unique amphipathic 
alpha-helix which is localized at the N-terminus [57, 58]. 
Limited proteolysis experiments recently allowed the 
definition of three protein domains within the cytosolic 
domain [59]. More recently, the three-dimensional 
structure of the N-terminal domain I could be resolved by 
crystallography. After dimerization, it forms a basic 
groove facing the cytosol at the surface of the membrane 
[60]. This 'claw like' structure is believed to provide an 
RNA binding site that could be involved in regulated 
genome targeting within the replication complex. 
5.4.5  NS5B 
The key enzyme of the replicase that promotes 
synthesis of new RNA genomes is the NS5B RNA-
dependent RNA polymerase (RdRp). NS5B is a tail-
anchored protein, characterized by a transmembrane 
domain at the C-terminus of the protein responsible for 
posttranslational membrane targeting [61-63]. The 
structural organization of NS5B is a typical 'right hand' 
polymerase shape with finger, palm, and thumb 
subdomains surrounding a completely encircled active 
site [64]. Replication proceeds via synthesis of a 
complementary minus-strand RNA using the genome as a 
template and the subsequent synthesis of genomic plus-
strand RNA from this minus-strand RNA intermediate. 
As central component of the HCV replicase, NS5B has 
emerged as a major target for antiviral intervention [44]. 
6. RNA replication 
As in all positive-strand RNA viruses investigated 
thus far (reviewed in ref. [65]), HCV forms a membrane-
associated replication complex, composed of viral 
proteins, replicating RNA, altered cellular membranes 
and additional host cell factors [50, 51]. A specific 
membrane alteration, referred to as the membranous web, 
was recently identified as the site of RNA replication in 
Huh-7 cells harboring subgenomic HCV replicons [51]. 
Thus, intracellular membranes play a crucial role in HCV 
replication. Recent data underline the importance of a 
specific lipid environment for HCV RNA replication [66, 
67]. 
In addition to coordinated protein-protein and 
protein-membrane interaction, essential cis-acting 
replication elements (CRE) of the RNA genome were 
recently discovered. For instance, the sequence coding for 
the C-terminal domain of NS5B consists of an essential 
stem-loop, designated SL3.2, within a larger cruciform 
RNA element, designated SL3 [68]. Detailed 
characterization of the SL3.2 domain indicated a 
functionally important kissing loop interaction with the 3' 
NCR [69]. 
Several host cell factors, including hVAP-A, FBL2 or 
cyclophylin B that influence HCV RNA replication via 
interaction with different viral proteins have been 
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identified [54, 70, 71]. However, the regulation of 
replication, the switch to translation or assembly and the 
release of viral particles are still poorly understood.  
7. Future research directions 
The pace of research in the HCV field has increased 
enormously with the establishment of the replicon system. 
The infectious JFH-1 cell culture system promises exiting 
progress in the understanding of steps in the viral life 
cycle that have been difficult to study thus far. In 
particular, HCV entry, cytoplasmic release and uncoating, 
the initial steps of replication, virus assembly, the release 
of viral progeny, and the detailed virion structure will be 
characterized in the infectious cell culture system. 
Furthermore, the impact of viral proteins such as p7 and 
NS2 for viral particle formation and possibly of NS5A for 
the switch between replication and assembly can be 
explored in this context. New insights into the molecular 
virology of HCV should identify novel targets for antiviral 
strategies.  
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